United Therapeutics Management
Management criteria checks 2/4
United Therapeutics' CEO is Martine Rothblatt, appointed in Jan 1996, has a tenure of 28.83 years. total yearly compensation is $16.96M, comprised of 8.7% salary and 91.3% bonuses, including company stock and options. directly owns 1.49% of the company’s shares, worth $242.22M. The average tenure of the management team and the board of directors is 15.6 years and 22.2 years respectively.
Key information
Martine Rothblatt
Chief executive officer
US$17.0m
Total compensation
| CEO salary percentage | 8.7% |
| CEO tenure | 28.8yrs |
| CEO ownership | 1.5% |
| Management average tenure | 15.6yrs |
| Board average tenure | 22.2yrs |
Recent management updates
Recent updates
United Therapeutics: One To Believe In Despite Competitive Threats
Nov 14Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 18
Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price
Sep 27United Therapeutics: Economics Support Compounding Ability
Aug 20With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jul 26United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market
Jun 13United Therapeutics: Exciting Company With A Big Problem
Jun 02We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$1b |
| Jun 30 2024 | n/a | n/a | US$1b |
| Mar 31 2024 | n/a | n/a | US$1b |
| Dec 31 2023 | US$17m | US$1m | US$985m |
| Sep 30 2023 | n/a | n/a | US$900m |
| Jun 30 2023 | n/a | n/a | US$872m |
| Mar 31 2023 | n/a | n/a | US$728m |
| Dec 31 2022 | US$5m | US$1m | US$727m |
| Sep 30 2022 | n/a | n/a | US$707m |
| Jun 30 2022 | n/a | n/a | US$631m |
| Mar 31 2022 | n/a | n/a | US$687m |
| Dec 31 2021 | US$4m | US$1m | US$476m |
| Sep 30 2021 | n/a | n/a | US$462m |
| Jun 30 2021 | n/a | n/a | US$471m |
| Mar 31 2021 | n/a | n/a | US$405m |
| Dec 31 2020 | US$5m | US$1m | US$515m |
| Sep 30 2020 | n/a | n/a | US$469m |
| Jun 30 2020 | n/a | n/a | US$430m |
| Mar 31 2020 | n/a | n/a | US$528m |
| Dec 31 2019 | US$46m | US$1m | -US$104m |
| Sep 30 2019 | n/a | n/a | -US$92m |
| Jun 30 2019 | n/a | n/a | -US$118m |
| Mar 31 2019 | n/a | n/a | -US$150m |
| Dec 31 2018 | US$16m | US$1m | US$589m |
| Sep 30 2018 | n/a | n/a | US$543m |
| Jun 30 2018 | n/a | n/a | US$713m |
| Mar 31 2018 | n/a | n/a | US$484m |
| Dec 31 2017 | US$37m | US$1m | US$418m |
Compensation vs Market: Martine's total compensation ($USD16.96M) is above average for companies of similar size in the US market ($USD12.74M).
Compensation vs Earnings: Martine's compensation has increased by more than 20% in the past year.
CEO
Martine Rothblatt (69 yo)
28.8yrs
Tenure
US$16,958,057
Compensation
Dr. Martine A. Rothblatt, Ph D., J.D., M.B.A., founded United Therapeutics Corporation in 1996 and has been its Chief Executive Officer since June 26, 2016 and as its Chairman since 1996. Dr. Rothblatt ser...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 28.8yrs | US$16.96m | 1.49% $ 242.2m | |
| President & COO | 8.4yrs | US$9.81m | 0.0058% $ 935.7k | |
| CFO & Treasurer | 11.8yrs | US$6.05m | 0.018% $ 2.9m | |
| Executive VP | 28.8yrs | US$5.15m | 0.082% $ 13.3m | |
| Head of Investor Relations | no data | no data | no data | |
| Associate Vice President of Human Resources | no data | no data | no data | |
| Senior Vice President of Strategic Operations & Logistics | no data | no data | no data | |
| Executive VP of Technical Operations | 15.6yrs | no data | no data | |
| Executive Vice President of Product Development & Xenotransplantation | no data | no data | no data | |
| Senior VP & Chief Medical Officer | no data | no data | no data |
15.6yrs
Average Tenure
56yo
Average Age
Experienced Management: UTHR's management team is seasoned and experienced (15.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 28.8yrs | US$16.96m | 1.49% $ 242.2m | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 22.8yrs | US$457.60k | 0.027% $ 4.4m | |
| Independent Director & Member of the Scientific Advisory Board | 22.2yrs | US$471.54k | 0.029% $ 4.7m | |
| Independent Director & Member of the Scientific Advisory Board | 22.8yrs | US$456.54k | 0.0039% $ 635.7k | |
| Independent Vice Chairman & Lead Independent Director | 22.1yrs | US$532.60k | 0.0045% $ 726.5k | |
| Independent Director | 21.3yrs | US$481.54k | 0.0082% $ 1.3m | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 22.8yrs | US$456.54k | 0.050% $ 8.2m | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 9.4yrs | US$488.66k | 0.013% $ 2.1m | |
| Independent Director | 15.6yrs | US$513.66k | 0.039% $ 6.3m |
22.2yrs
Average Tenure
76yo
Average Age
Experienced Board: UTHR's board of directors are seasoned and experienced ( 22.2 years average tenure).